Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease.

Phalen DN, Frimberger A, Pyecroft S, Peck S, Harmsen C, Lola S, de Mello Mattos B, Li KM, McLachlan AJ, Moore A.

PLoS One. 2013 Jun 6;8(6):e65133. doi: 10.1371/journal.pone.0065133. Print 2013.

2.

Doxorubicin and carboplatin trials in Tasmanian devils (Sarcophilus harrisii) with Tasmanian devil facial tumor disease.

Phalen DN, Frimberger AE, Peck S, Pyecroft S, Harmsen C, Lola S, Moore AS.

Vet J. 2015 Dec;206(3):312-6. doi: 10.1016/j.tvjl.2015.10.013. Epub 2015 Oct 13.

PMID:
26538144
3.

Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations.

Kreiss A, Brown GK, Tovar C, Lyons AB, Woods GM.

Vaccine. 2015 Jun 12;33(26):3016-25. doi: 10.1016/j.vaccine.2015.01.039. Epub 2015 Feb 20.

4.

Devil Facial Tumor Disease.

Pye RJ, Woods GM, Kreiss A.

Vet Pathol. 2016 Jul;53(4):726-36. doi: 10.1177/0300985815616444. Epub 2015 Dec 13. Review.

PMID:
26657222
5.

Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils.

Pye R, Hamede R, Siddle HV, Caldwell A, Knowles GW, Swift K, Kreiss A, Jones ME, Lyons AB, Woods GM.

Biol Lett. 2016 Oct;12(10). pii: 20160553. doi: 10.1098/rsbl.2016.0553.

6.

Pathogenesis and molecular biology of a transmissible tumor in the Tasmanian devil.

Bender HS, Marshall Graves JA, Deakin JE.

Annu Rev Anim Biosci. 2014 Feb;2:165-87. doi: 10.1146/annurev-animal-022513-114204. Epub 2013 Nov 18. Review.

PMID:
25384139
7.

Immunology of a Transmissible Cancer Spreading among Tasmanian Devils.

Woods GM, Howson LJ, Brown GK, Tovar C, Kreiss A, Corcoran LM, Lyons AB.

J Immunol. 2015 Jul 1;195(1):23-9. doi: 10.4049/jimmunol.1500131. Review.

8.

Mitogen-activated Tasmanian devil blood mononuclear cells kill devil facial tumour disease cells.

Brown GK, Tovar C, Cooray AA, Kreiss A, Darby J, Murphy JM, Corcoran LM, Bettiol SS, Lyons AB, Woods GM.

Immunol Cell Biol. 2016 Aug;94(7):673-9. doi: 10.1038/icb.2016.38. Epub 2016 Apr 19.

PMID:
27089941
9.

A murine xenograft model for a transmissible cancer in Tasmanian devils.

Kreiss A, Tovar C, Obendorf DL, Dun K, Woods GM.

Vet Pathol. 2011 Mar;48(2):475-81. doi: 10.1177/0300985810380398. Epub 2010 Sep 22.

PMID:
20861503
10.

Evolution in a transmissible cancer: a study of the chromosomal changes in devil facial tumor (DFT) as it spreads through the wild Tasmanian devil population.

Pearse AM, Swift K, Hodson P, Hua B, McCallum H, Pyecroft S, Taylor R, Eldridge MD, Belov K.

Cancer Genet. 2012 Mar;205(3):101-12. doi: 10.1016/j.cancergen.2011.12.001.

PMID:
22469509
11.

Tumor-specific diagnostic marker for transmissible facial tumors of Tasmanian devils: immunohistochemistry studies.

Tovar C, Obendorf D, Murchison EP, Papenfuss AT, Kreiss A, Woods GM.

Vet Pathol. 2011 Nov;48(6):1195-203. doi: 10.1177/0300985811400447. Epub 2011 Mar 7.

PMID:
21383118
12.

Discovery of Biomarkers for Tasmanian Devil Cancer (DFTD) by Metabolic Profiling of Serum.

Karu N, Wilson R, Hamede R, Jones M, Woods GM, Hilder EF, Shellie RA.

J Proteome Res. 2016 Oct 7;15(10):3827-3840. Epub 2016 Sep 23.

PMID:
27599268
13.

Biting injuries and transmission of Tasmanian devil facial tumour disease.

Hamede RK, McCallum H, Jones M.

J Anim Ecol. 2013 Jan;82(1):182-90. doi: 10.1111/j.1365-2656.2012.02025.x. Epub 2012 Sep 3.

PMID:
22943286
14.

Transmissible cancer in Tasmanian devils: localized lineage replacement and host population response.

Hamede RK, Pearse AM, Swift K, Barmuta LA, Murchison EP, Jones ME.

Proc Biol Sci. 2015 Sep 7;282(1814). pii: 20151468. doi: 10.1098/rspb.2015.1468.

15.

The pathology of devil facial tumor disease (DFTD) in Tasmanian Devils (Sarcophilus harrisii).

Loh R, Bergfeld J, Hayes D, O'hara A, Pyecroft S, Raidal S, Sharpe R.

Vet Pathol. 2006 Nov;43(6):890-5.

PMID:
17099145
16.

Natural killer cell mediated cytotoxic responses in the Tasmanian devil.

Brown GK, Kreiss A, Lyons AB, Woods GM.

PLoS One. 2011;6(9):e24475. doi: 10.1371/journal.pone.0024475. Epub 2011 Sep 21.

17.

The immunohistochemical characterization of devil facial tumor disease (DFTD) in the Tasmanian Devil (Sarcophilus harrisii).

Loh R, Hayes D, Mahjoor A, O'Hara A, Pyecroft S, Raidal S.

Vet Pathol. 2006 Nov;43(6):896-903.

PMID:
17099146
18.

Trophic cascades following the disease-induced decline of an apex predator, the Tasmanian devil.

Hollings T, Jones M, Mooney N, McCallum H.

Conserv Biol. 2014 Feb;28(1):63-75. doi: 10.1111/cobi.12152. Epub 2013 Sep 11.

PMID:
24024987
19.

The Tasmanian devil transcriptome reveals Schwann cell origins of a clonally transmissible cancer.

Murchison EP, Tovar C, Hsu A, Bender HS, Kheradpour P, Rebbeck CA, Obendorf D, Conlan C, Bahlo M, Blizzard CA, Pyecroft S, Kreiss A, Kellis M, Stark A, Harkins TT, Marshall Graves JA, Woods GM, Hannon GJ, Papenfuss AT.

Science. 2010 Jan 1;327(5961):84-7. doi: 10.1126/science.1180616.

20.

Assessment of cellular immune responses of healthy and diseased Tasmanian devils (Sarcophilus harrisii).

Kreiss A, Fox N, Bergfeld J, Quinn SJ, Pyecroft S, Woods GM.

Dev Comp Immunol. 2008;32(5):544-53. Epub 2007 Oct 16.

PMID:
17988737

Supplemental Content

Support Center